TROPION-Lung01 Study Design and Baseline demographics
Probability of progression-free survival
1.0
BEGONIA Arm 7: Dato-DXd + Durvalumab
Progression-Free Survival and Duration of Response
Median PFS was 13.8 months (95% CI, 11.0-NC)
Median DoR was 15.5 months (95% CI, 9.92-NC)
Durva + Dato-DXd (N=62)
0.9
0.8
0.7
0.6
0.5
0.4.
0.3
0.2
0.1
0.0
T T
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Time from first dose date (months)
Duration and onset of objective response
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
T
Durva + Dato-DXd (N=62)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Time from first dose date (months)
Number of patients at risk
Durva +
Dato-DXd
62 61 56 55 54 52 45 40 37 32 24 23 18 18 14 13 13 2 2 0
Number of patients at risk
Durva +
Dato-DXd
49 49 49 47 46 42 35 30 28 21 18 17 17 13 13 12 1 1 0
Kaplan-Meier analysis was performed. Circles indicate censored observations.
CI, confidence interval; Dato-DXd, datopotamab deruxtecan; DoR, duration of response; NC, not calculable; PFS, progression-free survival.
Data cutoff: 02 Feb 2023
40
Daiichi-SankyoView entire presentation